Free Trial

BioNTech Q4 2022 Earnings Report

BioNTech logo
$113.08 +1.74 (+1.56%)
(As of 05:31 PM ET)

BioNTech EPS Results

Actual EPS
$9.26
Consensus EPS
$8.04
Beat/Miss
Beat by +$1.22
One Year Ago EPS
$13.93

BioNTech Revenue Results

Actual Revenue
$4.28 billion
Expected Revenue
$3.87 billion
Beat/Miss
Beat by +$413.00 million
YoY Revenue Growth
-22.70%

BioNTech Announcement Details

Quarter
Q4 2022
Time
Before Market Opens

Conference Call Resources

What Joe Biden got right (Ad)

Anyone with a brain knows Joe Biden failed this country from day one. But, even I must admit there is one thing the Biden administration did right. I call this tech, “The AI Keystone.” It’s the number-one way to capitalize on the trillion-dollar artificial intelligence market.

check out my new report.

BioNTech Earnings Headlines

Comparing Senti Biosciences (NASDAQ:SNTI) and BioNTech (NASDAQ:BNTX)
What Joe Biden got right
Anyone with a brain knows Joe Biden failed this country from day one. But, even I must admit there is one thing the Biden administration did right. I call this tech, “The AI Keystone.” It’s the number-one way to capitalize on the trillion-dollar artificial intelligence market.
J.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)
FDA Lifts Hold on BioNTech’s Key Cancer Trial
See More BioNTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNTech and other key companies, straight to your email.

About BioNTech

BioNTech (NASDAQ:BNTX), a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

View BioNTech Profile

More Earnings Resources from MarketBeat

Upcoming Earnings